Open AccessProstate Cancer, Use of Androgen Deprivation Therapy, and Cognitive Impairment
Author(s) -
Hector J. Alonso Quiñones,
Bradley J. Stish,
Clinton E. Hagen,
Ronald C. Petersen,
Michelle M. Mielke
Publication year - 2019
Publication title -
alzheimer disease and associated disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 95
eISSN - 1546-4156
pISSN - 0893-0341
DOI - 10.1097/wad.0000000000000366
Subject(s) - prostate cancer , androgen deprivation therapy , odds ratio , medicine , rochester epidemiology project , confidence interval , population , logistic regression , epidemiology , oncology , cancer , gynecology , population based study , environmental health
The association of prostate cancer and androgen deprivation therapy (ADT) use with the odds of developing mild cognitive impairment (MCI) was determined in men from the population-based Mayo Clinic Study of Aging (MCSA).